Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Assessment of energy expenditure

The mechanisms underlying the reduction in body weight produced by novel anti-obesity drugs should always be investigated by measuring the effects of the compound on both sides of the energy equation balance.

 

We offer a fully comprehensive metabolic profiling service using the TSE PhenoMaster system. This 16-cage indirect calorimetry system, equipped with motion sensors and automated food and water hoppers, can be used to determine the effects of novel test drugs on energy expenditure.  The following parameters can be measured simultaneously to elucidate the mode of action underpinning weight loss effects:

  • Oxygen consumption (VO2)
  • Carbon dioxide production (VCO2)
  • Energy expenditure (derived from VO2and VCO2)
  • Respiratory exchange ratio (RER; an estimate of relative substrate utilisation, ie shifts in fat and carbohydrate utilisation)
  • Food and water intake
  • Meal and drink patterns (ie frequency and size)
  • Ambulatory and rearing activity (measured as beam breaks)).

 

The TSE PhenoMaster can be used to study mice or rats.

 

The beta-3 adrenoceptor agonist, CL-316,243, increases energy expenditure in the dietary-induced obese (DIO) mouse

The beta-3 adrenoceptor agonist, CL-316,243, increases utilization of fat (reduces RER) in the dietary-induced obese (DIO) mouse

 

Get in touch for more information or browse our models of metabolic disorders.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.